Huntington's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 75 years old
- You are able to give your informed consent to take part
- You are able to read and speak English
- You are willing to follow the study procedures, which include fasting overnight, having blood taken, and having a lumbar puncture (a procedure where a small amount of fluid is taken from your lower back)
- You have either been diagnosed with Huntington's disease (HD) or have not been diagnosed with HD
Who may not be able to join:
- You are younger than 18 or older than 75 years old
- You carry a specific intermediate or very large number of CAG gene repeats (a genetic variation related to HD) — confirm with trial site if unsure what this means for you
- You receive your nutrition through a feeding tube
- You are pregnant
- You have taken part in a clinical drug trial in the last 30 days
- You take prescribed or non-prescribed medications that may affect blood clotting or cause excessive bleeding
- You have tested positive for HIV, hepatitis B, or hepatitis C
- You have a confirmed or suspected condition that weakens your immune system
- You have a significant medical, psychiatric, or neurological condition on the day of sample collection that may prevent you from completing the study procedures (confirm with trial site)
- You have a fear of needles, frequent headaches, a significant problem with your lower spine, or have had major surgery
- You have taken blood-thinning or anti-clotting medications (such as aspirin, warfarin, or similar drugs) within the 14 days before sample collection
- You have a disorder that affects blood clotting or causes unusual bruising
- You are unwilling or unable to follow any of the study procedures
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Amber Southwell, PhD, University of Central Florida Burnett School of Biomedical Sciences
Phone: 4072668742
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To discover blood-based biomarker of brain HTT protein using extracellular vesicles to be used in evaluating target engagement in HTT lowering clinical trials.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.